Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
122M
-
Number of holders
-
53
-
Total 13F shares, excl. options
-
48.8M
-
Shares change
-
+5.35M
-
Total reported value, excl. options
-
$117M
-
Value change
-
+$12.8M
-
Put/Call ratio
-
0
-
Number of buys
-
37
-
Number of sells
-
-12
-
Price
-
$2.39
Significant Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q2 2023
60 filings reported holding TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q2 2023.
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) has 53 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.8M shares
of 122M outstanding shares and own 40.17% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (11.4M shares), Frazier Life Sciences Management, L.P. (6.88M shares), Rubric Capital Management LP (5.68M shares), Fairmount Funds Management LLC (5.19M shares), VIKING GLOBAL INVESTORS LP (4.4M shares), VR Adviser, LLC (3.42M shares), BlackRock Inc. (2.23M shares), VANGUARD GROUP INC (1.91M shares), Opaleye Management Inc. (1.7M shares), and MAI Capital Management (1.53M shares).
This table shows the top 53 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.